The Chan Zuckerberg Initiative (CZI) research organization has developed a new artificial intelligence (AI) model, the GREmLN, which is implemented for in-depth study of cellular processes leading to the development of diseases. The findings of the study have been published on the bioRxiv pre-publication platform.

The aforesaid model is designed to identify mechanisms associated with the development of cancer, neurodegenerative disorders, and other pathologies.

Unlike traditional methods for analyzing large amounts of data, the GREmLN independently models the interaction networks between genes, and this enables to determine changes in cell function in the early stages of the disease and identify potential targets for therapy.

The GREmLN was trained on data from the CellxGene platform. It is an online resource that stores hundreds of publicly available data for single-cell research. The platform contains information about 93 million unique cells from the brain, lungs, kidneys, blood, and other organs.

The platform also includes other models, such as TranscriptFormer, which combines genetic data from different types of living organisms to study the work of cells in more detail.

All tools are open to researchers and can be used to develop early diagnostic methods, predict cell responses to drugs, and create personalized treatment regimens.